Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer

Summary

The majority of small cell lung cancer(SCLC)(50-100%) express somatostatin receptors(type 1-5) with some small cell lung cancer express more than one subtypes. Stimulation of these SSTR's lead to inhibition of angiogenesis and cell growth. SOM230 also lower levels of IGF which is known to contribute to SCLC proliferation. Topotecan is approved for second line therapy in relapsed small cell lung cancer. We hypothesized that combination of both agents should yield greater antitumor activity.

Timeline

Start

2011-07

Primary completion

2016-06

Completion

2016-12

Drugs

Indications